Nieren und Diabetes

Schlüsselwörter

Diabetes mellitus - Nephropathie - Proteinurie - Kreatinin

Key words

diabetes mellitus - nephropathy - proteinuria - creatinine

Literatur

• 1 Adler A I, Stevens R J, Manley S E. et al . Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).  Kidney Int. 2003;  63 225-232
• 2 Barnett A H, Bain S C, Bouter P. et al . Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.  N Engl J Med. 2004;  351 1952-1961
• 3 Bertoni A G, Krop J S, Anderson G F, Brancati F L. Diabetes-related morbidity and mortality in a national sample of U.S. elders.  Diabetes Care. 2002;  25 471-475
• 4 Deutsche Hochdruckliga e. V. DHL® – Deutsche Hypertonie Gesellschaft . Leitlinien zur Diagnostik und Behandlung der arteriellen Hypertonie.  Nieren- und Hochdruckkrankheiten. 2005;  34 481-498
• 5 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.  Lancet. 2000;  355 253-259
• 6 European Society of Hypertension – European Society of Cardiology . Guidelines for the management of arterial hypertension.  J Hypertens. 2003;  21 1011-1053
• 7 Fisher E B, Thorpe C T, Devellis B M, Devellis R F. Healthy coping, negative emotions, and diabetes management: a systematic review and appraisal.  Diabetes Educ. 2007;  33 1080-1103; discussion 1104 – 1086
• 8 Frei U, Schober-Halstenberg H J. Nierenersatztherapie in Deutschland. QuaSi-Niere Jahresbericht 2005/2006, Berlin, Deutschland. 
• 9 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.  Lancet. 1999;  353 617-622
• 10 Goede P, Lund-Andersen H, Parving H H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  358 580-591
• 11 Harding G K, Zhanel G G, Nicolle L E, Cheang M. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria.  N Engl J Med. 2002;  347 1576-1583
• 12 Hasslacher C, Kempe P, Ritz E, Wolf G. Diabetische Nephropathie. DDG Praxis-Leitlinie.  Diabetologie. 2007;  2 S159-S162
• 13 Helmchen U, Kneissler U, Velden J, Stahl R AK. Nierenbiopsiebefunde bei Diabetes mellitus.  Der Diabetologe. 2006;  2 419-431
• 14 Kastelein J J, Akdim F, Stroes E S. et al . Simvastatin with or without ezetimibe in familial hypercholesterolemia.  N Engl J Med. 2008;  358 1431-1443
• 15 Keech A, Simes R J, Barter P. et al . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study).  Lancet. 2005;  366 1849-1861
• 16 MacIsaac R J, Panagiotopoulos S, McNeil K J. et al . Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?.  Diabetes Care. 2006;  29 1560-1566
• 17 Meiland R, Geerlings S E, Stolk R P. et al . Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up.  Arch Intern Med. 2006;  166 2222-2227
• 18 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals.  Lancet. 2002;  360 7-22
• 19 National Institutes of Health .For Safety. NHLBI Changes Intensive Blood Sugar Treatment Strategy in Clinical Trial of Diabetes and Cardiovascular Disease. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id = 2551. last vistited 2.3.2008. 
• 20 Ogawa Y, Goto T, Tamasawa N. et al . Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy.  Diabetes Res Clin Pract. 2008;  79 357-361
• 21 Pinkau T, Hilgers K F, Veelken R, Mann J F. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease?.  J Am Soc Nephrol. 2004;  15 517-523
• 22 Pucci L, Triscornia S, Lucchesi D. et al . Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients.  Clin Chem. 2007;  53 480-488
• 23 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 24 Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease.  J Am Soc Nephrol. 2006;  17 2985-2991
• 25 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 Suppl 2 B21-29
• 26 Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.  J Am Med Assoc. 2003;  290 2159-2167
• 27 The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.  Diabetes. 1996;  45 1289-1298
• 28 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. UK Prospective Diabetes Study Group.  BMJ. 1998;  317 703-713
• 29 Tuomilehto J, Lindstrom J, Eriksson J G. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 30 Winocour P H. Effective diabetes care: a need for realistic targets.  BMJ. 2002;  324 1577-1580
• 31 Wolf G, Muller N, Mandecka A, Muller U A. Association of diabetic retinopathy and renal function in patients with types 1 and 2 diabetes mellitus.  Clin Nephrol. 2007;  68 81-86
• 32 Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management.  J Am Soc Nephrol. 2003;  14 1396-1405
• 33 Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.  Kidney Int. 2005;  67 799-812